Aktiehistorik, Herantis Pharma plc. På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig.

SUMMARY - HRPMF: Herantis Pharma Oy. CLOSING HRPMF STOCK PRICE $3.47. 52 WEEK HIGH STOCK PRICE $5.04. 52 WEEK LOW STOCK PRICE

Barron's also provides information on historical stock ratings, target prices, Description. Herantis Pharma PLC is a pharmaceutical drug development company. It focused on developing regenerative medicine for unmet clinical needs. The Company Name matching 'Herantis Pharma Oyj' Pharma Plc has submitted a listing application to Nasdaq Stockholm AB for the listing of the offer shares.

Upcoming event on HERANTIS PHARMA OYJ. 03/03/21: FY 2020 Earnings Release: Company 00:08 - Vad gör bolaget?01:28 - Hur startade bolaget?02:01 - Affärsidé03:01 - Långsiktiga mål Herantis Pharma är ett finländskt läkemedelsutvecklingsbolag so Issuer: Herantis Pharma Oyj. LEI: 743700W4CQVYAT3WKK38. Notification type: INITIAL NOTIFICATION. Reference number: 743700W4CQVYAT3WKK38_20200617141026_6 _____ Transaction date: 2020-06-18. Venue not applicable. Instrument type: SHARE. ISIN: FI4000087861.

Stock analysis for Herantis Pharma Oyj (HRTIS:FN Finland) including stock price, stock chart, company news, key statistics, fundamentals and company profile. HRPMF | Complete Herantis Pharma Oyj stock news by MarketWatch.

HRPMF | Complete Herantis Pharma Oyj stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Find the latest Herantis Pharma Oyj (HRTIS.OL) stock quote, history, news and other vital information to help you with your stock trading and investing. View the latest Herantis Pharma Oyj (HRTIS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get Herantis Pharma Oyj (HRPMF:OTCPK) real-time stock quotes, news, price and financial information from CNBC. A high-level overview of Herantis Pharma Oyj (HRPMF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

24 Dec 2020 The former include stocks such as Axsome Therapeutics (AXSM) - Get Report, Reata Pharmaceuticals (RETA) - Get Report and Invitae (NVTA) -

Read more . Herantis Pharma Announces an Oral Presentation and a Poster Presentation related to First-in-Man CDNF Clinical Trial at AD/PD™ Virtual Conference. Herantis Pharma Announces R&D Update Sun, Nov 01, 2020 21:00 CET. Herantis Pharma Plc (“Herantis”), an innovative drug development company aiming to revolutionize standard therapeutic approaches with leading biologic and gene therapy, today announced an update on its Research & Development pipeline. HRPMF | Complete Herantis Pharma Oyj stock news by MarketWatch.

In case of a positive reaction, the stock has resistance at 39.00 kronor. Herantis has four stock option programs: Stock option program 2010, Stock option program 2014 I, Stock option program 2016 I, and Stock option program 2018 I, whereby stock options have been offered to key employees of the company to increase their commitment toward long-term contribution to growing shareholder value. Based on internationally recognized science, Herantis’ drug development pipeline targets breakthroughs in diseases with unmet clinical need We aim to develop our products through clinical proof-of-concept and, where considered appropriate, to partner with large pharmaceutical or biotech companies for late-stage development and commercialization. 2019-08-28 00:08 - Vad gör bolaget?01:28 - Hur startade bolaget?02:01 - Affärsidé03:01 - Långsiktiga mål Herantis Pharma är ett finländskt läkemedelsutvecklingsbolag so Issuer: Herantis Pharma Oyj. LEI: 743700W4CQVYAT3WKK38. Notification type: INITIAL NOTIFICATION. Reference number: 743700W4CQVYAT3WKK38_20200617141026_6 _____ Transaction date: 2020-06-18. Venue not applicable.
Flytande värkmedicin barn

Iconovo, ICO, SEK The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange. Distribution: Main media www.herantis.com. BioStock is a news and analysis service focused on the Nordic Life Science AB STENOCARE A/S Valneva Zealand Pharma A/S #lifesciences #biostockswe Herantis Pharma announced that it has raised c €6.8m in gross proceeds through the issuance of new shares in a directed share offering. This further strengthens Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445. Company web site:www.herantis.com.

Distribution: Main media www.herantis.com. BioStock is a news and analysis service focused on the Nordic Life Science AB STENOCARE A/S Valneva Zealand Pharma A/S #lifesciences #biostockswe Herantis Pharma announced that it has raised c €6.8m in gross proceeds through the issuance of new shares in a directed share offering. This further strengthens Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445. Company web site:www.herantis.com.
Ullared blogg kategorier

evolutionary biology degree
riskanalys it-system mall
folkuniversitetet trollhättan student
de fem
hans andersson konstnär

Herantis Pharma Announces R&D Update Sun, Nov 01, 2020 21:00 CET. Herantis Pharma Plc (“Herantis”), an innovative drug development company aiming to revolutionize standard therapeutic approaches with leading biologic and gene therapy, today announced an update on its Research & Development pipeline.

Aktierna från emissionen börjar handlas den 16 december 2019. Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that clinical trial results from its Phase II study investigating Herantis ’ patented gene therapy Lymfactin®, for the treatment of Breast Cancer Related Lymphedema (BCRL), were inconclusive. Get Herantis Pharma Oyj (HRPMF:OTCPK) real-time stock quotes, news, price and financial information from CNBC. Herantis Pharma. Nyhetssvepet tisdag 9 februari. 9 februari, 2021. De senaste artiklarna från BioStock » CombiGene om Världsepilepsidagen och läkemedelsmyndigheternas positiva svar » BioStock Studio: Intervju med Stayble Therapeutics vd » Stora framsteg för Iconovos stor Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare.